@article {2386, title = {Association of Triglyceride and Glucose Index with Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes Mellitus Patients}, journal = {Pharmacognosy Journal}, volume = {16}, year = {2024}, month = {October 2024}, pages = {1077- 1080}, type = {Original Article}, chapter = {1077}, abstract = {

Introduction: Non-alcoholic fatty liver disease (NAFLD) is significantly linked to obesity, insulin resistance (IR), metabolic syndrome, and type 2 diabetes (T2DM). There isn{\textquoteright}t a single biomarker used to diagnose NAFLD. Objectives: Analyzing the association between triglyceride and glucose index (TyG) with NAFLD in T2DM. Methods: This cross-sectional study aimed to assess the efficacy of TyG as a potential NAFLD biomarker. The study was conducted on 103 diabetes outpatient clinics at the Dr. Soetomo General Academic Hospital from August to October 2023. Sixty-seven subjects experienced steatosis, while those who did not experience steatosis were 36. The statistical analysis used in this study is binary logistic regression with p \<0.05. Results: The receiver operating characteristic curves (ROC) analysis showed a TyG cut-off value of 9.334 (AUC = 0.660). Analysis of the risk of TyG on the incidence of steatosis was carried out using binary logistic regression. The results showed that TyG was a significant risk factor for steatosis. Patients with a TyG value above 9.334 risk developing steatosis 3.567 times greater than patients with a TyG value below 9.334 (OR 95\% = 1.373 {\textendash} 9.270, p = 0.009). Conclusion: A significant association between TyG and NAFLD in T2DM patients, which the TyG index may be a more effective, valuable, and uncomplicated measure for detecting and controlling NAFLD.

}, keywords = {Hepatic steatosis, Insulin resistance, NAFLD, TyG index, Type 2 diabetes mellitus}, doi = {10.5530/pj.2024.16.174}, author = {Febri Kurniawati and Sony Wibisono Mudjanarko and Soebagijo Adi Soelistijo and Titong Sugihartono} } @article {2423, title = {Potential Molecular level Impact of Cresvin beta on Type 2 Diabetes Mellitus: A Randomized Controlled Clinical Trial}, journal = {Pharmacognosy Journal}, volume = {16}, year = {2024}, month = {December 2024}, pages = {1297-1304}, type = {Original Article}, chapter = {1297}, abstract = {

Background: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with an increasing prevalence rate over the past few decades. Despite the availability of medications to prevent and reduce disease severity, T2DM prevalence and incidence continue to rise annually. Understanding genetic heritage{\textquoteright}s impact on therapeutic responses is improving, with pharmacogenetics being used to better comprehend the therapeutic variability of T2DM. This study aims to compare the effects of metformin and Cresvin beta capsules containing Pterocarpus marsupium, Withania somnifera, Salacia reticulata, Gymnema Sylvestre, Curcuma longa, Vitis vinifera and Piper nigrum (Black pepper extract) on diabetic and immune-related gene expression in T2DM patients. Methods: Sixty patients were divided into two groups: metformintreated (group A, n=30) and Cresvin beta -treated (group B, n=30). Anthropometric, biochemical, and hematological parameters were measured at baseline and after 3 months of treatment. Gene expression levels were analyzed using quantitative real-time polymerase chain from DNA extracted from whole blood samples. Results: After 3 months, metformin significantly reduced fasting blood sugar (FBS), postprandial blood sugar (PPBS), and HbA1c levels (p\<0.001). Cresvin beta also significantly reduced FBS (p\<0.01), PPBS (p\<0.001), and HbA1c (p\<0.001). Gene expression analysis showed significant changes in SIRT1, AKT, SLC2A4, IL-6, and TNF-α in both groups. Conclusion: The study demonstrated that Cresvin beta reduced glycemic levels and improved SIRT1, Pi3k, Akt, and SLC2A4 gene expression while decreasing IL-6 and TNF-α cytokine gene expression in T2DM patients.

}, keywords = {anti-diabetic efficacy, Ayurveda, Cresvin beta, Metformin, Sirtuin 1, Type 2 diabetes mellitus}, doi = {10.5530/pj.2024.16.209}, author = {Nandakumar K N and Mohanraj Nehru and Prasanth Subramanian and Bhuvaneshwaran Mothiswaran and Vishagan S S and Satishkumar Rajappan Chandra and Venkataraman Prabhu} } @article {2310, title = {Serum Trace Element Levels in Type 2 DM Patients and its Correlation with Glycemic Control}, journal = {Pharmacognosy Journal}, volume = {16}, year = {2024}, month = {June 2024}, pages = {660-663}, type = {Research Article}, chapter = {660}, abstract = {

Background: Type 2 diabetes mellitus, a chronic metabolic disorder, is known to impact serum trace element levels. Objectives: to investigates the association between serum trace elements (Co, Cr, and Cu) and glycemic control in individuals with type 2 diabetes. Material and Methods: A 209 type 2 diabetes patients from Dr. H. Abdul Moeloek Hospital in Bandar Lampung and Hasan Sadikin Hospital in Bandung participated in the study. Patients underwent assessments for serum trace element levels (Co, Cr, and Cu) and glycemic control indicators (FBG and HbA1c). Results: Results indicated significantly lower Co levels in uncontrolled diabetes versus controlled cases (P\<0.05). Co, Cr, and Cu levels displayed a significant negative correlation with HbA1c (P\<0.05), while Cr and Cu showed a significant negative correlation with FBG (P\<0.05). Age did not show significant correlations with serum trace element levels. Conclusion: serum trace element levels (Co, Cr, Cu) are inversely linked to glycemic control in type 2 diabetes individuals.

}, keywords = {Fasting blood glucose, glycemic control, HbA1c, trace element serum, Type 2 diabetes mellitus}, doi = {10.5530/pj.2024.16.104}, author = {Intanri Kurniati and Agustyas Tjiptaningrum and Raja Iqbal Mulya Harahap and Bayu Putra Danan Jaya} } @article {1074, title = {The Antioxidant and Hypoglycemic Properties and Phytochemical Profile of Clusia latipes Extracts}, journal = {Pharmacognosy Journal}, volume = {12}, year = {2020}, month = {February 2020}, pages = {144-149}, type = {Research Article}, chapter = {144}, abstract = {

Introduction: The prevalence of diabetes has increased more rapidly in low and middleincome countries than in high-income countries. Type 2 diabetes mellitus (DM2), which is the most common form of diabetes, is caused by the inefficient use of insulin in the body and is characterized by disrupted insulin action or secretion. Also, oxidative stress plays an important role in the development of disease. The goal of this study is to identify the antioxidant and hypoglycemic properties of Clusia latipes, an endemic species of Central and South America. Methods: The antioxidant and hypoglycemic capacity of the extracts (hexane, ethyl acetate, and methanol) of the leaves and stems of Clusia latipes were evaluated. From the most potent extract, the phytochemical study was carried out and fractionated. Antioxidant activity was measured using 2,2-diphenyl-1-picrylhydrazyl (DPPH) and 2,2-azinobis (3-ethylbenzothiazoline- 6-sulfonic acid) diammonium salt (ABTS), while hypoglycemic capacity was measured by alpha-glucosidase inhibition. Results: The extracts with the highest antioxidant capacity are the extracts with the highest α-glucosidase inhibition activity. Inhibitory activity increased in samples extracted with medium polar (ethyl acetate) and polar (methanol) solvents. Phytochemical screening of these extracts revealed the presence of alkaloids, carbohydrates, flavonoids/xanthones, quinones, saponins, and tannins. The highest α-glucosidase inhibitory activity was detected in the ethyl acetate fraction obtained from leaf methanol extract, with a half-maximal inhibitory concentration (IC50) value of 0.90 μg/ml. The major constituent isolated from the same fraction was isoquercitrin.

}, keywords = {DPPH, Phytochemical screening, Type 2 diabetes mellitus, α-glucosidase inhibitory activity}, doi = {10.5530/pj.2020.12.21}, author = {Ronald Silva-Rivas and Natalia Bailon-Moscoso and Luis Cartuche and Juan Carlos Romero-Benavides} } @article {1112, title = {Correlation between the in-vitro and in-vivo Antihyperglycemic Effect of Ocimum Sanctum, Trigonella Foenum Graecum and Curcuma Longa}, journal = {Pharmacognosy Journal}, volume = {12}, year = {2020}, month = {March 2020}, pages = {369-376}, type = {Research Article}, chapter = {369}, abstract = {

This study is carried out to investigate the correlation between the in-vitro and in-vivo studies which demonstrates the antihyperglycemic effect of Trigonella foenum graecum, Ocimum sanctum and Curcuma longa extracts. Methanolic seed extract of Trigonella foenum graecum, methanolic leaf extract of Ocimum sanctum, ethyl acetate rhizomes extract of Curcumina longa are prepared and supplied by Sami labs, Bangalore, India on request. in-vitro studies such as alpha glucosidase inhibitory and DPP-IV inhibitory activity were done for all the three extracts as per previous studies. After Institutional animal ethical committee clearance male albino rats (155{\textendash}215 g) were divided into 5 groups. Each group consists of randomly assigned 6 albino rats. The placebo (Normal saline) control group, Standard (Vildagliptin) group and 3 above mentioned extract groups. Oral glucose tolerance test (OGTT) was done. Blood samples were collected for blood sugar estimation at -30 (before extract),0, 15, 45 minutes and blood sugar levels were done by enzymatic assay. Results: The maximum alpha-glucosidase inhibitory activity at 100 μg/ml by Trigonella foenum graecum extract was 68\% with IC50 value of 57.25, Ocimum sanctum leaf extract was 65\% with IC50 value of 59.55, Curcuma longa was 72\% with IC50 value of 56.79 when compared to the Acarbose (STD) of 94\% with IC50 values of 42.78. The maximum \% of DPP IV inhibition at 320 μg/ml of Trigonella foenum graecum extract was 77.84\% with IC50 value of 52.26, Ocimum sanctum extract was 86.98\% with IC50 value of 46.08 and Curcuma longa was 76.47\% with IC50 value of 55.06 when compared to the Vildagliptin (STD) was 80.15\% with IC50 value of 22.98. The OGTT results of Ocimum sanctum (200 mg/kg) shows reduction in blood glucose (p=\<0.05) at 15 minutes and significant reduction (p=\<0.001) at 45 minutes and Trigonella foenum graecum (2 gm/kg) showed significant reduction in blood glucose (p=\<0.001) at 15 minutes when compared to control. Further clinical studies are necessary to establish the therapeutic potential of these extracts in the treatment of type 2 diabetes mellitus. Conclusion: Ocimum sanctum leaf extract, Trigonella foenum graecum seed extract shows significant alpha-glucosidase and DPPIV inhibitory activity which correlates with the antihyperglycemic effects by in-vivo oral glucose tolerance test. Further clinical studies are necessary to establish the therapeutic potential of these extracts in the treatment of type 2 diabetes mellitus.

}, keywords = {Curcuma longa, GLP-1, Glucagon, Insulin, Ocimum sanctum, Trigonella foenum graecum, Type 2 diabetes mellitus}, doi = {10.5530/pj.2020.12.58}, author = {Inbaraj SD and Muniappan M} }